In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtent and the Next DES Boom

Executive Summary

Safety concerns and a retrenchment in usage have dimmed the luster of drug-eluting stents, but only slightly. If the market is to turn around and, more importantly, serve the kind of patients who really need these devices, a second-generation drug-eluting stent will be needed, one designed specifically for these new patients. And Xtent believe it has the technology to do just that.
Advertisement

Related Content

Proving Device Incubation Works: An Interview with The Foundry
Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market
The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs
Thriving When the Device IPO Window Closes
Thriving When The Device IPO Window Closes
ART: Bucking the Trend in Bioabsorbable Stents
VCs Keep Capital Flowing To Stent Start-Ups
Business and Technology Briefs
CardioMind: Big Solutions to Small Problems
Conor: An Outsider Delivers Drug-Stents' Next Generation

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel